Nomura Asset Management Co. Ltd. Sells 5,290 Shares of Bio-Rad Laboratories, Inc. $BIO

Nomura Asset Management Co. Ltd. trimmed its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 95.3% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 260 shares of the medical research company’s stock after selling 5,290 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Bio-Rad Laboratories were worth $63,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd boosted its position in Bio-Rad Laboratories by 3,633.3% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock valued at $27,000 after buying an additional 109 shares during the period. Quarry LP purchased a new position in Bio-Rad Laboratories during the first quarter valued at $29,000. UMB Bank n.a. grew its stake in shares of Bio-Rad Laboratories by 89.8% in the second quarter. UMB Bank n.a. now owns 167 shares of the medical research company’s stock worth $40,000 after acquiring an additional 79 shares during the last quarter. Headlands Technologies LLC boosted its stake in Bio-Rad Laboratories by 64.1% in the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock worth $87,000 after purchasing an additional 139 shares in the last quarter. Finally, Twin Tree Management LP purchased a new stake in shares of Bio-Rad Laboratories during the first quarter valued at approximately $87,000. 65.24% of the stock is owned by institutional investors.

Insider Activity at Bio-Rad Laboratories

In related news, EVP James Barry sold 700 shares of the firm’s stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $306.18, for a total value of $214,326.00. Following the completion of the sale, the executive vice president owned 510 shares in the company, valued at $156,151.80. This trade represents a 57.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 17.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BIO shares. Wells Fargo & Company boosted their target price on shares of Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research report on Thursday, October 30th. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday. Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Citigroup raised their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada boosted their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Price Performance

BIO stock opened at $316.92 on Monday. Bio-Rad Laboratories, Inc. has a 1 year low of $211.43 and a 1 year high of $373.69. The firm has a market capitalization of $8.55 billion, a PE ratio of -13.04 and a beta of 1.04. The business has a 50 day simple moving average of $304.72 and a 200-day simple moving average of $272.79. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67.

Bio-Rad Laboratories (NYSE:BIO) last announced its earnings results on Wednesday, October 29th. The medical research company reported $2.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.30 by ($0.04). Bio-Rad Laboratories had a negative net margin of 26.43% and a positive return on equity of 4.18%. The firm had revenue of $653.00 million during the quarter, compared to analysts’ expectations of $651.30 million. During the same period in the previous year, the firm earned $2.01 EPS. The firm’s revenue for the quarter was up .5% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.